Dare Bioscience Investor Presentation Deck

Clinical Issue Limitations with current standards of care Target Product Profile Bacterial Vaginosis 1.https://www.cdc.gov/std/bv/stats.htm Recurring infection, difficult to treat effectively Most common vaginal condition in women ages 15-44 Affects ~21 million women in the US¹ Bacterial Vaginosis increases health risks², including increased risk of preterm birth, sexually transmitted infections, post-surgical infection, and pelvic inflammatory disease that can increase the risk of infertility Bacterial vaginosis is a disruption in the optimal vaginal microbiome and therefore recurrent in many women Women experiencing recurrence have three or more episodes in the same year, and may not prefer multiple doses of systemic antibiotics Current Rx suboptimal: clinical cure rates of 37-68%³ Single self-administered dose, any time of day Vaginal delivery of the antibiotic, with minimal systemic exposure Colorless, odorless gel Demonstrated equivalent cure rates in both women having her first occurrence of bacterial vaginosis as well as those with a history of multiple prior episodes Clear labeling for special populations such as pregnant and lactating women Daré Innovation: XACIATOTM (Clindamycin Phosphate) Vaginal Gel, 2%* 2.https://www.mayoclinic.org/diseases-conditions/bacterial-vaginosis/symptoms-causes/syc-20352279 3. Bacterial vaginosis product data: http://www.clindesse.com/pdf/Pl.pdf; http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/2052235000lbl.pdf; http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/2052235000lbl.pdf * See Full Prescribing Information 17

View entire presentation